BioVaxys Technology Corp. (CSE:BIOV)
Canada flag Canada · Delayed Price · Currency is CAD
0.0500
0.00 (0.00%)
Apr 2, 2025, 11:33 AM EST

BioVaxys Technology Cash Flow Statement

Millions CAD. Fiscal year is Nov - Oct.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Oct '24 Oct '23 Oct '22 Oct '21 Oct '20 2019
Net Income
-3.95-7.69-11.73-6.46-1.17
Upgrade
Asset Writedown & Restructuring Costs
1.291.457.4--
Upgrade
Stock-Based Compensation
0.33.250.621.250.35
Upgrade
Other Operating Activities
0.45-0.250.23-00.07
Upgrade
Change in Accounts Payable
0.691.81.98-0.50.18
Upgrade
Change in Other Net Operating Assets
-0.640.39-0.070.42-0.63
Upgrade
Operating Cash Flow
-1.86-1.05-1.57-5.29-1.23
Upgrade
Cash Acquisitions
----0.04
Upgrade
Sale (Purchase) of Intangibles
-1.06----
Upgrade
Other Investing Activities
----0.02
Upgrade
Investing Cash Flow
-1.06---0.06
Upgrade
Short-Term Debt Repaid
-0.03----
Upgrade
Total Debt Repaid
-0.03----
Upgrade
Net Debt Issued (Repaid)
-0.03----
Upgrade
Issuance of Common Stock
3.160.921.133.783.33
Upgrade
Other Financing Activities
---0.03-0.340.02
Upgrade
Financing Cash Flow
3.130.921.113.443.35
Upgrade
Foreign Exchange Rate Adjustments
0-00.020.030.01
Upgrade
Net Cash Flow
0.21-0.14-0.45-1.832.19
Upgrade
Levered Free Cash Flow
-4.014.06-0.74-2.71-0.06
Upgrade
Unlevered Free Cash Flow
-4.014.06-0.74-2.71-0.06
Upgrade
Change in Net Working Capital
1.31-2.31-1.020.22-0.22
Upgrade
Updated Mar 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.